Imiquimod 5% cream for treatment of HIV-negative Kaposi’s sarcoma skin lesions: A phase I to II, open-label trial in 17 patients - 24/04/13
, Sylvie Chevret, MD, PhD b, Carolina Paz, MD a, Delphine Kerob, MD a, Olivier Verola, MD c, Patrice Morel, MD a, Céleste Lebbé, MD, PhD a
Reprint requests: Noël Emile Célestin Schartz, MD, PhD, Hôpital Saint Louis, Policlinique de dermatologie, 1, avenue Claude Vellefaux, F – 75475 Paris Cedex 10, France.Abstract |
Background |
Kaposi’s sarcoma (KS), a virus-associated neoplasm, can be treated locally or systemically with interferon alfa. Therefore, imiquimod, an immune response modifier able to induce interferon-⍺ secretion in situ, could prove a good local treatment for KS skin lesions.
Objective |
We sought to determine the efficacy and safety of imiquimod 5% cream for the topical treatment of classic or endemic KS skin lesions in patients who are HIV negative.
Methods |
We conducted a prospective, open-label, single center, phase II clinical trial. Imiquimod cream was applied under occlusion 3 times a week for 24 weeks. The main efficacy end points were the safety of topical imiquimod and the overall clinical response in patients evaluated on the basis of modified AIDS Clinical Trials Group criteria at 36 weeks. The statistical analysis was based on the intent-to-treat data set.
Results |
Seventeen patients were enrolled. Eight (47%) presented objective overall clinical response (2 complete and 6 partial responses). Tumor progression was noted in 6 patients. The most frequent side effects were local itching and erythema, seen in 9 patients (53%).
Limitations |
This was not a randomized placebo-controlled study and was restricted to a small number of patients.
Conclusion |
Topical imiquimod 5% cream had antitumor activity in about half the patients with classic and endemic KS and was generally well tolerated.
Le texte complet de cet article est disponible en PDF.Abbreviations used : ACTG, CR, IFN, IL, KS, PD, PR
Plan
| Supported by a grant-in-aid from 3M Pharmaceuticals. |
|
| Conflicts of interest: None declared. |
Vol 58 - N° 4
P. 585-591 - avril 2008 Retour au numéro
Article précédent
- Demographic and clinical properties of juvenile-onset Behçet’s disease: A controlled multicenter study
- Yelda Karincaoglu, Murat Borlu, Semra Cikman Toker, Ayse Akman, Meltem Onder, Suhan Gunasti, Aysegul Usta, Basak Kandi, Cicek Durusoy, Muammer Seyhan, Serap Utas, Hayriye Saricaoglu, Muge Guler Ozden, Soner Uzun, Umit Tursen, Demet Cicek, Levent Donmez, Erkan Alpsoy
- Total skin electron beam therapy may be associated with improvement of peripheral blood disease in Sézary syndrome
- Camille E. Introcaso, Bizhan Micaily, Stephen K. Richardson, Jacqueline M. Junkins-Hopkins, Jessica S. Yoon, Ellen J. Kim, Carmela C. Vittorio, Alain H. Rook
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?